Obstructive lung diseases and beta-blockers: Where do we stand?

Published: 11 May 2016
Author(s): Helena Pité, Marisa Braga da Cruz, Mário Morais-Almeida
Issue: May 2016
Section: Letters to the Editor

Cardiovascular diseases are major public health problems. ß-blockers therapy is indicated for the majority of patients with heart failure and coronary artery disease (Class I, Level of Evidence: A). These drugs are also first-line therapy for atrial fibrillation. However, ß-blocker use continues to be less than optimal, principally in patients with concomitant chronic obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).